Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction-A New Endpoint from Old Clinical Trials

被引:2
作者
Niedziela, Jacek T. [1 ,2 ]
Gasior, Mariusz [1 ,2 ]
机构
[1] Silesian Ctr Heart Dis, Dept Cardiol 3, PL-41800 Zabrze, Poland
[2] Med Univ Silesia, Fac Med Sci Zabrze, Dept Cardiol 3, PL-40752 Katowice, Poland
关键词
heart failure; clinical trials; endpoints; methodology; CARDIAC-RESYNCHRONIZATION THERAPY; VENTRICULAR SYSTOLIC FUNCTION; CONVERTING-ENZYME INHIBITORS; GISSI-HF TRIAL; RANDOMIZED-TRIAL; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; MORTALITY; CANDESARTAN; MORBIDITY;
D O I
10.3390/jcm11195518
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Most of the drugs approved and registered for use in heart failure (HF) therapy were examined in randomized clinical trials (RCTs) with the primary composite endpoint of death or hospital readmission. This study aimed to analyze the rates of the newly calculated event: death without prior hospital readmission, in HFrEF patients in large RCTs to show that the newly defined endpoint probably delivers additional data on the structure of the composite endpoint and helps to interpret the results of interventional studies. Methods: This study included RCTs on therapeutic interventions in HF patients. A literature search was performed, and 31 trials in which death without hospital admission could be calculated were included in the analyses. The death without a prior hospital admission endpoint was calculated as the difference between the composite endpoint rate (death or hospital readmission) and the readmission rate. The differences in the new endpoint between the study groups were calculated. Result: The death rates without prior hospital admission were lower in the intervention groups in five trials. In the SENIORS study, significant differences were found in the primary (composite) and death without previous hospital admission endpoints. In the ACCLAIM, VEST, and GISSI-HF STATIN trials, death without previous hospital admission was the only endpoint with a significant difference between the study groups. Moreover, the new endpoint rates were higher in the intervention group in the latter two studies. Conclusions: The new endpoint describing patients who died without prior hospital admission might be useful in previous and future interventional studies to provide additional data on the structure of the composite endpoint. Some therapies might reduce death without previous hospital admission rates, which could be beneficial, even without a reduction in overall long-term mortality.
引用
收藏
页数:10
相关论文
共 37 条
[1]  
Cleland J.G.F., 2005, INDIAN HEART J, V57, P186, DOI [10.1111/j.1527-5299.2005.04176.x, DOI 10.1111/J.1527-5299.2005.04176.X]
[2]   A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure [J].
Cohn, JN ;
Goldstein, SO ;
Greenberg, BH ;
Lorell, BH ;
Bourge, RC ;
Jaski, BE ;
Gottlieb, SO ;
McGrew, F ;
DeMets, DL ;
White, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25) :1810-1816
[3]   Rehospitalization for Heart Failure Predict or Prevent? [J].
Desai, Akshay S. ;
Stevenson, Lynne W. .
CIRCULATION, 2012, 126 (04) :501-506
[4]   FASTTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) [J].
Flather, MD ;
Shibata, MC ;
Coats, AJS ;
Van Veldhuisen, DJ ;
Parkhomenko, A ;
Borbola, J ;
Cohen-Solal, A ;
Dumitrascu, D ;
Ferrari, R ;
Lechat, P ;
Soler-Soler, J ;
Tavazzi, L ;
Spinarova, L ;
Toman, J ;
Böhm, M ;
Anker, SD ;
Thompson, SG ;
Poole-Wilson, PA .
EUROPEAN HEART JOURNAL, 2005, 26 (03) :215-225
[5]   NONFATAL MYOCARDIAL-INFARCTION IS, BY ITSELF, AN INAPPROPRIATE END-POINT IN CLINICAL-TRIALS IN CARDIOLOGY [J].
FLEISS, JL ;
BIGGER, JT ;
MCDERMOTT, M ;
MILLER, JP ;
MOON, T ;
MOSS, AJ ;
OAKES, D ;
ROLNITZKY, LM ;
THERNEAU, TM .
CIRCULATION, 1990, 81 (02) :684-685
[6]   Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial [J].
Gheorghiade, Mihai ;
Boehm, Michael ;
Greene, Stephen J. ;
Fonarow, Gregg C. ;
Lewis, Eldrin F. ;
Zannad, Faiez ;
Solomon, Scott D. ;
Baschiera, Fabio ;
Botha, Jaco ;
Hua, Tsushung A. ;
Gimpelewicz, Claudio R. ;
Jaumont, Xavier ;
Lesogor, Anastasia ;
Maggioni, Aldo P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (11) :1125-1135
[7]   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].
Granger, CB ;
McMurray, JJV ;
Yusuf, S ;
Held, P ;
Michelson, EL ;
Olofsson, B ;
Östergren, J ;
Pfeffer, MA ;
Swedberg, K .
LANCET, 2003, 362 (9386) :772-776
[8]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[9]   Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial [J].
Konstam, Marvin A. ;
Neaton, James D. ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Komajda, Michel ;
Martinez, Felipe A. ;
Riegger, Gunter A. J. ;
Malbecq, William ;
Smith, Ronald D. ;
Guptha, Soneil ;
Poole-Wilson, Philip A. .
LANCET, 2009, 374 (9704) :1840-1848
[10]   Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].
McMurray, J. J. V. ;
Solomon, S. D. ;
Inzucchi, S. E. ;
Kober, L. ;
Kosiborod, M. N. ;
Martinez, F. A. ;
Ponikowski, P. ;
Sabatine, M. S. ;
Anand, I. S. ;
Belohlavek, J. ;
Bohm, M. ;
Chiang, C. -E. ;
Chopra, V. K. ;
de Boer, R. A. ;
Desai, A. S. ;
Diez, M. ;
Drozdz, J. ;
Dukat, A. ;
Ge, J. ;
Howlett, J. G. ;
Katova, T. ;
Kitakaze, M. ;
Ljungman, C. E. A. ;
Merkely, B. ;
Nicolau, J. C. ;
O'Meara, E. ;
Petrie, M. C. ;
Vinh, P. N. ;
Schou, M. ;
Tereshchenko, S. ;
Verma, S. ;
Held, C. ;
DeMets, D. L. ;
Docherty, K. F. ;
Jhund, P. S. ;
Bengtsson, O. ;
Sjostrand, M. ;
Langkilde, A. -M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008